Enhanced virological response to treatment with 40 kDa peginterferon alfa-2A (PEGASYS®) in patients previously unresponsive to treatment with interferon alfa-2A: Gerald Y Minuk, University of Manitoba, Winnipeg, MB Canada; K. Rajender Reddy, University of Miami School of Medicine, Miami, FL; Samuel S Lee, University of Calgary, Calgary, AB Canada; E. Jenny Heathcote, Toronto Western Hospital, Toronto, ON Canada; John O'Grady, King's College School of Medicine, London Uk; Paul J Pockros, The Scripps Clinic, La Jolla, CA; Mitchell L Shiffman, Medical College of Virginia, Richmond, VA; Nikolai V Naoumov, University College London, London Uk; Farhad Sedarati, Jean Depamphilis, Hoffmann-La Roche, Nutley, NJ